Show MeBlood cancer statistics show that roughly 1 in 9 cancers diagnosed in the United States is a blood cancer, and about 6.5% of Americans will develop one in their lifetime. In 2026, an estimated 198,000 new cases will be diagnosed across leukemia, lymphoma, and myeloma, with five-year relative survival averaging 70% to 73% overall. Survival ranges from roughly 40% for acute myeloid leukemia to over 90% for Hodgkin lymphoma, and incidence has been rising about 0.5% to 1% per year for most subtypes since the 1990s. These figures come from the American Cancer Society's 2026 projections and the National Cancer Institute's SEER program.
What Counts as Blood Cancer
Blood cancer is an umbrella term for malignancies that start in bone marrow, lymph nodes, or blood cells. The three major families are leukemia, lymphoma, and multiple myeloma. Leukemia arises from immature white blood cells in the marrow. Lymphoma arises from lymphocytes that accumulate in lymph nodes. Myeloma arises from plasma cells that crowd out normal marrow. Each family contains subtypes with wildly different biology, treatment, and prognosis.
This matters for reading statistics because the subtypes behave like separate diseases. A headline figure for "blood cancer survival" averages indolent lymphomas that patients live with for decades against acute leukemias that can kill within weeks. The averaging hides more than it reveals.
In plain terms: blood cancer statistics are useful only when broken down by subtype and age group.
How Blood Cancers Develop: The Mechanism Behind the Numbers
Every blood cancer starts with a genetic error in a single hematopoietic stem cell or its descendant. That error gives the cell a survival or growth advantage. The cell divides, its clone expands, and it accumulates additional mutations over months to years. Chronic leukemias accumulate mutations slowly and present with high cell counts but few symptoms. Acute leukemias arise from a small number of mutations and produce rapid marrow failure.
The location of the malignant cell determines the clinical picture. Marrow crowding stops red cell, platelet, and normal white cell production, which causes anemia, bleeding, and infection risk. Lymph node accumulation causes swelling and systemic symptoms. Plasma cell expansion produces abnormal antibodies that damage kidneys and bones.
This mechanism explains the age pattern in the statistics. Most blood cancers require multiple mutations over decades, so incidence rises steeply with age. Roughly 60% of leukemia cases and about 55% of myeloma cases occur in people aged 65 or older. Hodgkin lymphoma is the major exception, with a first peak in the 20s.
Latest Blood Cancer Statistics: Incidence and Survival by Subtype
The table below shows estimated 2026 new cases and five-year relative survival for the major subtypes, based on American Cancer Society and SEER data.
| Subtype | Estimated 2026 new US cases | Five-year relative survival | Median age at diagnosis |
|---|---|---|---|
| Non-Hodgkin lymphoma | 82,000 | 74% | 68 |
| Multiple myeloma | 37,000 | 60% | 69 |
| Chronic lymphocytic leukemia | 23,000 | 88% | 70 |
| Acute myeloid leukemia | 22,000 | 35% | 68 |
| Hodgkin lymphoma | 9,000 | 92% | 39 |
| Acute lymphocytic leukemia | 6,500 | 72% | 17 |
| Chronic myeloid leukemia | 7,000 | 70% | 66 |
Myeloma also includes a smaller group of plasma cell disorders, so read the 37,000 figure as new myeloma diagnoses only. The acute lymphocytic leukemia median age of 17 reflects a bimodal pattern: about 60% of cases occur in children and young adults, who survive far better than adults over 60.
Quantified Comparison: Blood Cancer Versus Solid Tumors
Blood cancers differ from solid tumors in ways that shape the statistics. A quantified comparison makes the gap concrete.
| Measure | Blood cancers | Solid tumors (all sites) | Difference |
|---|---|---|---|
| Five-year relative survival, all stages | About 72% | About 68% | Blood cancers modestly higher |
| Share of US cancer diagnoses | About 9% | About 91% | Blood cancers are a minority |
| Share of US cancer deaths | About 9.5% | About 90.5% | Slightly higher death share |
| New drugs approved 2015-2025 | 51 | 63 | Comparable pace |
| Five-year survival improvement since 2000 | About 9 percentage points | About 6 percentage points | Blood cancers improved faster |
The improvement gap is the most striking number. Blood cancer survival rose roughly 9 percentage points between 2000 and 2020, compared with 6 percentage points for solid tumors. Targeted therapies drove most of that gain. Imatinib pushed chronic myeloid leukemia survival from roughly 30% in 2000 to about 70% today, and CAR-T cell therapy pushed refractory diffuse large B-cell lymphoma five-year survival from under 10% to roughly 40% in trial cohorts.
Variations by Age, Sex, and Geography
Age is the strongest risk factor. Incidence of most blood cancers roughly doubles with each decade after age 40. Acute myeloid leukemia incidence rises from about 1 case per 100,000 people under 40 to roughly 20 per 100,000 over 70. Hodgkin lymphoma breaks the pattern with a peak in the 20s and a second, smaller peak after 55.
Sex differences are consistent but modest. Men have about a 30% to 40% higher incidence of non-Hodgkin lymphoma and leukemia than women. Myeloma is about 1.4 times more common in men.
Geography reveals occupational and environmental signals. Non-Hodgkin lymphoma rates are roughly 2 to 3 times higher in industrialized countries than in most of sub-Saharan Africa and parts of Asia. Some of that gap is diagnostic access, but the consistency of the pattern across decades suggests real environmental contributions.
Race affects outcomes more than incidence. Black Americans diagnosed with multiple myeloma have roughly 20% higher mortality than White Americans at the same stage, a gap partly linked to delayed diagnosis and differences in access to newer therapies.
Timeline: Milestones in Blood Cancer Outcomes
| Period | Milestone | Survival impact |
|---|---|---|
| 1970s | Combination chemotherapy for childhood ALL | Five-year survival rose from under 10% to over 70% |
| 1990s | Rituximab added to lymphoma regimens | DLBCL five-year survival rose from about 45% to about 65% |
| 2001 | Imatinib approved for chronic myeloid leukemia | Five-year survival rose from about 30% to about 70% |
| 2006 | Lenalidomide improves myeloma outcomes | Median survival rose from about 3 years to 7-8 years |
| 2013 | Ibrutinib approved for CLL | CLL five-year survival rose past 85% |
| 2017 | First CAR-T therapies approved | Refractory lymphoma responders show durable remissions |
| 2020s | Bispecific antibodies for myeloma | Deep response rates in heavily pretreated patients |
Common Misconceptions About Blood Cancer Statistics
The most frequent misconception is that rising incidence means blood cancers are becoming more common in a biological sense. In reality, age-adjusted incidence for most subtypes has been flat or rising only 0.5% to 1% per year. Part of the apparent rise is better detection through imaging and blood work.
A second misconception is that survival statistics tell you what will happen to you. Relative survival compares diagnosed patients against the general population, so it cannot account for your age, subtype, stage, or molecular profile. A patient diagnosed with chronic lymphocytic leukemia at 55 may face a near-normal life expectancy. A patient diagnosed with acute myeloid leukemia at 75 may face a two-year median.
A third misconception is that blood cancer equals leukemia. Leukemia accounts for about 35% of new blood cancer diagnoses and slightly under 40% of blood cancer deaths. Lymphoma and myeloma make up the rest and behave very differently.
What to Actually Do With These Numbers
- Focus on your subtype, not the aggregate. Ask your care team for the five-year survival figure for your exact diagnosis, stage, and molecular profile.
- Ask about age-adjusted comparisons. A 40-year-old with acute myeloid leukemia has roughly double the five-year survival of a 75-year-old with the same diagnosis.
- Request molecular testing at diagnosis. NPM1, FLT3, and cytogenetic results change both prognosis and treatment for AML.
- For myeloma, ask about treatment line and response depth. Being in a deep response after first-line therapy roughly triples expected survival.
- Interpret survival figures as population averages, not personal predictions.
- Check that your data are recent. Five-year survival figures from 2015 are outdated for chronic lymphocytic leukemia and multiple myeloma.
Limitations of Blood Cancer Statistics
All blood cancer statistics carry caveats. Registry data lag by two to four years, so 2026 figures are statistical projections, not headcounts. Survival figures are relative survival, which compares patients to the general population of the same age and sex, not absolute survival. Reporting completeness varies by subtype, and indolent lymphomas are undercounted because some patients are never formally diagnosed.
Stage reporting is another limitation. Blood cancers use disease-specific staging (Rai for CLL, ISS for myeloma, Ann Arbor for lymphoma) that does not map onto the solid tumor stages most people expect. Comparing "stage 2" blood cancer to "stage 2" breast cancer is meaningless.
Finally, trial-based survival numbers apply to trial-eligible patients, who tend to be younger and healthier than the real-world population. Real-world five-year survival for acute myeloid leukemia in patients over 70 is roughly 15% to 20%, well below the 35% average quoted for all ages combined. Treat every statistic here as a starting point for a conversation with an oncologist, not a personal forecast.